AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or...AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or in the light/dark test after both acute andchronic treatments. RESULTS: S-21007 presentedanxiolytic-like properties after acute administration inthe light/dark box test, the mirrored chamber test, andthe elevated plus-maze at be doses 10 ng·kg^(-1)-100μg·kg^(-1), 1-100 μg·kg^(-1) and 10-100 μg·kg^(-1),respectively. In the light/dark box test, S-21007 wasactive orally after acute treatment at 100 ng·kg^(-1)-10mg·kg^(-1) and after chronic treatment (14 d) at 1-10μg·kg^(-1). S-21007 was devoid of sedative or stimula-展开更多
文摘AIM: To study the effect of S-21007, a 5-HT_3partial agonist in different animal models of anxiety inmice. METHODS: S-21007 effects were evaluatedin the behavior tests after intraperitioneal and oral acutetreatment or in the light/dark test after both acute andchronic treatments. RESULTS: S-21007 presentedanxiolytic-like properties after acute administration inthe light/dark box test, the mirrored chamber test, andthe elevated plus-maze at be doses 10 ng·kg^(-1)-100μg·kg^(-1), 1-100 μg·kg^(-1) and 10-100 μg·kg^(-1),respectively. In the light/dark box test, S-21007 wasactive orally after acute treatment at 100 ng·kg^(-1)-10mg·kg^(-1) and after chronic treatment (14 d) at 1-10μg·kg^(-1). S-21007 was devoid of sedative or stimula-
